{"id":819121,"date":"2025-02-27T08:08:49","date_gmt":"2025-02-27T13:08:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/"},"modified":"2025-02-27T08:08:49","modified_gmt":"2025-02-27T13:08:49","slug":"bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/","title":{"rendered":"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial"},"content":{"rendered":"

\nEleison to leverage BullFrog Data Networks\u2122\u00a0to enhance patient clustering and safety analysis in glufosfamide clinical trials
\n<\/h2>\n
\n

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc.<\/a>\u00a0(NASDAQ: BFRG; BFRGW) (\u201cBullFrog AI\u201d or the \u201cCompany\u201d), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmaceuticals Inc. (\u201cEleison\u201d), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers. Under the terms of the agreement, BullFrog AI will provide access to its BullFrog Data Networks\u2122 AI solution to enhance clinical trial efficiency and patient insights. Financial terms of the collaboration were not disclosed.<\/p>\n

\u201cThe integration of artificial intelligence in clinical trials represents a transformative shift in how pharmaceutical companies can de-risk drug development and optimize patient outcomes,\u201d said Vin Singh, CEO of BullFrog AI. \u201cWe are thrilled to partner with Eleison to apply our bfLEAP\u00ae<\/sup> AI technology, which has the potential to refine patient selection, improve trial efficiency, and ultimately accelerate the path to market for life-saving therapies.\u201d<\/p>\n

Through this collaboration, BullFrog AI will apply its proprietary BullFrog Data Networks\u2122 solution, powered by the bfLEAP\u00ae<\/sup> platform, to analyze clinical data from Eleison\u2019s ongoing Phase 3 trial and previous clinical studies of glufosfamide, an investigational treatment for pancreatic cancer. The platform will evaluate the current trajectory of the trial with respect to safety signals, extract predictive biomarkers for efficacy and safety performance from prior studies to support future trial design, and provide data-driven insights to optimize Eleison\u2019s planned clinical trials for inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). These insights are expected to streamline trial efficiency and improve decision-making for Eleison\u2019s broader oncology pipeline.<\/p>\n

Glufosfamide is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects. It is currently being evaluated by Eleison in a pivotal Phase 3 international randomized clinical trial, for the second-line treatment of patients with pancreatic cancer. Although pancreatic cancer is among the rarer cancer types, it is the third leading cause of death by cancer in the United States. More than 67,000 Americans and 510,000 people worldwide are diagnosed with pancreatic cancer annually. Few therapeutic options exist to treat the disease and five-year survival rates are typically less than 5%. Eleison expects to complete this ongoing Phase 3 trial in 2027.<\/p>\n

\u201cOur collaboration with BullFrog AI underscores our commitment to innovation in drug development,\u201d said Edwin Thomas, CEO of Eleison. \u201cBy leveraging AI-powered analytics, we aim to generate deeper insights into patient responses and safety trends, which will not only benefit our glufosfamide program but also inform the strategic direction of our broader oncology pipeline.\u201d<\/p>\n

\n About BullFrog AI<\/strong>\n <\/p>\n

BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP\u2122 platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.<\/p>\n

For more information, visit BullFrog AI at: https:\/\/bullfrogai.com<\/a><\/p>\n

\n About Eleison Pharmaceuticals<\/strong>\n <\/p>\n

Eleison\u2019s mission is to acquire and develop drug candidates with existing and significant safety and efficacy data; and ultimately to obtain regulatory approval and commercialize new therapeutics for patients with life-threatening cancers. In addition to its glufosfamide program, the Company has two other programs in late-stage clinical development; ILC in development for small cell lung cancer and pediatric osteosarcoma, and DBD for brain cancers. The Company has entered into development and marketing partnerships with leading pharmaceutical companies in China, S. Korea, and Israel. Eleison was founded in 2009 and is headquartered in Princeton, NJ. Additional information about Eleison can be found at our website www.eleison-pharma.com<\/a>.<\/p>\n

Safe Harbor Statement<\/p>\n

This press release contains forward-looking statements. We base these forward-looking\u00a0statements on our expectations and projections about future events, which we derive from\u00a0the information currently available to us. Such forward-looking statements relate to future\u00a0events or our future performance, including: our financial performance and projections; our\u00a0growth in revenue and earnings; and our business prospects and opportunities. You can\u00a0identify forward-looking statements by those that are not historical in nature, particularly\u00a0those that use terminology such as “may,” “should,” \u201ccould,\u201d \u201cwill,\u201d “expects,” “anticipates,” “contemplates,”\u00a0“estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative\u00a0of these or similar terms. In evaluating these forward-looking statements, you should\u00a0consider various factors, including: our ability to change the direction of the Company; our\u00a0ability to keep pace with new technology and changing market needs; and the competitive\u00a0environment of our business. These and other factors may cause our actual results to differ\u00a0materially from any forward-looking statement. Forward-looking statements are only\u00a0predictions. The forward-looking events discussed in this press release and other\u00a0statements made from time to time by us or our representatives, may not occur, and actual\u00a0events and results may differ materially and are subject to risks, uncertainties, and\u00a0assumptions about us. We are not obligated to publicly update or revise any forward-looking\u00a0statement, whether as a result of uncertainties and assumptions, the forward-looking events\u00a0discussed in this press release and other statements made from time to time by us or our\u00a0representatives might not occur.<\/p>\n

Contact:<\/p>\n

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
BFRG@redchip.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Eleison to leverage BullFrog Data Networks\u2122\u00a0to enhance patient clustering and safety analysis in glufosfamide clinical trials GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc.\u00a0(NASDAQ: BFRG; BFRGW) (\u201cBullFrog AI\u201d or the \u201cCompany\u201d), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmaceuticals Inc. (\u201cEleison\u201d), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers. Under the terms of the agreement, BullFrog AI will provide access to its BullFrog Data Networks\u2122 AI solution to enhance clinical trial efficiency and patient insights. Financial terms of the collaboration were not disclosed. \u201cThe integration of artificial … <\/p>\n

Continue reading “BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819121","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Eleison to leverage BullFrog Data Networks\u2122\u00a0to enhance patient clustering and safety analysis in glufosfamide clinical trials GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc.\u00a0(NASDAQ: BFRG; BFRGW) (\u201cBullFrog AI\u201d or the \u201cCompany\u201d), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmaceuticals Inc. (\u201cEleison\u201d), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers. Under the terms of the agreement, BullFrog AI will provide access to its BullFrog Data Networks\u2122 AI solution to enhance clinical trial efficiency and patient insights. Financial terms of the collaboration were not disclosed. \u201cThe integration of artificial … Continue reading "BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T13:08:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial\",\"datePublished\":\"2025-02-27T13:08:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/\"},\"wordCount\":892,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/\",\"name\":\"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=\",\"datePublished\":\"2025-02-27T13:08:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/","og_locale":"en_US","og_type":"article","og_title":"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial - Market Newsdesk","og_description":"Eleison to leverage BullFrog Data Networks\u2122\u00a0to enhance patient clustering and safety analysis in glufosfamide clinical trials GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc.\u00a0(NASDAQ: BFRG; BFRGW) (\u201cBullFrog AI\u201d or the \u201cCompany\u201d), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its entry into a collaboration agreement with Eleison Pharmaceuticals Inc. (\u201cEleison\u201d), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers. Under the terms of the agreement, BullFrog AI will provide access to its BullFrog Data Networks\u2122 AI solution to enhance clinical trial efficiency and patient insights. Financial terms of the collaboration were not disclosed. \u201cThe integration of artificial … Continue reading \"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T13:08:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial","datePublished":"2025-02-27T13:08:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/"},"wordCount":892,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/","name":"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=","datePublished":"2025-02-27T13:08:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NTg3NSM2NzgyMDM0IzIyNTU4NDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bullfrog-ai-and-eleison-pharmaceuticals-enter-agreement-to-collaborate-to-optimize-pivotal-phase-3-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819121"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819121\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}